Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 18 , ISSUE 12 ( December, 2014 ) > List of Articles


Alteco endotoxin hemoadsorption in Gram-negative septic shock patients

Hoi-Ping Shum, Yuk Wah Leung,, Sin Man Lam,, King Chung Chan,, Wing Wa Yan

Keywords : Endotoxins, hemoadsorption, septic shock, outcome

Citation Information : Shum H, Leung, YW, Lam, SM, Chan, KC, Yan WW. Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J Crit Care Med 2014; 18 (12):783-788.

DOI: 10.4103/0972-5229.146305

License: CC BY-ND 3.0

Published Online: 01-03-2009

Copyright Statement:  Copyright © 2014; The Author(s).


Background and Aims: Severe sepsis and septic shock are common causes of mortality and morbidity in an intensive care unit setting. Endotoxin, derived from the outer membranes of Gram-negative bacteria, is considered a major factor in the pathogenesis of sepsis. This study investigated the effect of Alteco endotoxin hemoadsorption device on Gram-negative septic shock patients. Materials and Methods: An open, controlled, prospective, randomized, single-center trial was conducted between February 2010 and June 2012. Patients with septic shock due to intra-abdominal sepsis were randomized to either conventional therapy (n = 8) or conventional therapy plus two 2-hourly sessions of Alteco endotoxin hemoadsorption (n = 7). Primary endpoint was the Sequential Organ Failure Assessment (SOFA) score changes from 0 to 72 h. Secondary end points included vasopressor requirement, PaO 2 /FiO 2 ratio (PFR), length of stay (LOS), and 28-day mortality. Results: This study was terminated early as interim analysis showed a low probability of significant findings. No significant difference was noted between the two groups with respect to change in SOFA score, vasopressor score, PFR, LOS, and 28-day mortality. Side-effect was minimal. Conclusions: We could not identify any clinical benefit on the addition of Alteco endotoxin hemoadsorption to conventional therapy in patients who suffered from intra-abdominal sepsis with shock. The side effect profile of this novel device was acceptable.

PDF Share
  1. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
  2. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7:167-202.
  3. Positional cloning of Lps, and the general role of toll-like receptors in the innate immune response. Eur Cytokine Netw 2000;11:143-52.
  4. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis 2004;190:527-34.
  5. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097-102.
  6. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995;23:994-1006.
  7. Application of polymyxin B convalently immobilized fiber in patients with septic shock. Contrib Nephrol 2010;166:150-7.
  8. Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review. Crit Care 2007;11:R47.
  9. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
  10. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
  11. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
  12. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.
  13. A new endotoxin adsorber in septic shock: Observational case series. Blood Purif 2011;32:303-9.
  14. Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today′s critically ill patients. Crit Care Med 2006;34:1297-310.
  15. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
  16. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004;32:2318-22.
  17. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
  18. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009;37:803-10.
  19. High-volume hemofiltration in the intensive care unit: A blood purification therapy. Anesthesiology 2012;116:1377-87.
  20. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Med 2013;39:1535-46.
  21. Techniques of extracorporeal cytokine removal: A systematic review of the literature. Blood Purif 2012;33:88-100.
  22. Coupled plasma filtration adsorption. Contrib Nephrol 2007;156:405-10.
  23. Effects of coupled plasma filtration adsorption on septic patients with multiple organ dysfunction syndrome. Ren Fail 2012;34:834-9.
  24. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock. Shock 2011;36:332-8.
  25. A new endotoxin adsorber: First clinical application. Ther Apher 2001;5:326-34.
  26. A new endotoxin adsorption device in Gram-negative sepsis: Use of immobilized albumin with the MATISSE adsorber. Transfus Apher Sci 2003;29:93-8.
  27. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 2004;32:1662-8.
  28. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol Scand 2008;52:1024-5.
  29. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purif 2009;28:227-33.
  30. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care 2003;18:115-20.
  31. Endotoxemia in pediatric critical illness - A pilot study. Crit Care 2011;15:R141.
  32. Endotoxin activity level and septic shock: A possible role for specific anti-endotoxin therapy? Contrib Nephrol 2010;167:102-10.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.